Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

Narendiran Rajasekaran, PhDMSc, Mohith Sadaram, BS, Jonathan Hebb, MD, Idit Sagiv-Barfi, PhD, Sid Ambulkar, Amanda Rajapaksa, Serena Chang, PhD, Cariad Chester, Erin Waller, Lai Wang, PhD, Brian Lannutti, PhD, Dave Johnson, Ron Levy, MD, Holbrook E Kohrt, MD PhD

Blood (2014) 124 (21): 3118.

https://doi.org/10.1182/blood.V124.21.3118.3118

Published: 2014

Journal Articles

The PI3K Delta Inhibitor Idelalisib Interferes With Pre-B Cell Receptor Signaling In Acute Lymphoblastic Leukemia (ALL): A New Therapeutic Concept

Nathalie Y. Rosin, PhD, Ekaterina Kim, MS, Stefan Koehrer, MD, Zhiqiang Wang, Ph.D., Susan O'Brien, MD, William G. Wierda, MD, Deborah A. Thomas, MD, Zeev Estrov, MD, Hagop M. Kantarjian, MD, Brian Lannutti, PhD, Richard E. Davis, PhD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 2632.

https://doi.org/10.1182/blood.V122.21.2632.2632

Published: 2013

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

Sarah A Meadows, BS, Adam Kashishian, BS, Dave Johnson, Volker Diehl, Brian Lannutti, PhD

Blood (2010) 116 (21): 3926.

https://doi.org/10.1182/blood.V116.21.3926.3926

Published: 2010

Journal Articles

Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurslike Cells (NLC), In Chronic Lymphocytic Leukemia

Julia Hoellenriegel, Sarah A Meadows, William G. Wierda, MD, PhD, Michael J Keating, MD, Brian Lannutti, PhD, Jan A. Burger, MD, PhD

Blood (2010) 116 (21): 48.

https://doi.org/10.1182/blood.V116.21.48.48

Published: 2010

Journal Articles

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Richard R. Furman, MD, John C. Byrd, MD, Jennifer R Brown, MD, PhD, Steven E. Coutre, MD, Don M Benson, Jr., MD, Nina D. Wagner-Johnston, Ian W. Flinn, MD, PhD, Brad S. Kahl, MD, Stephen E. Spurgeon, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Heather K Webb, Ph.D., Roger G Ulrich, Ph.D., Sissy Peterman, Leanne M. Holes, Albert S Yu, MD

Blood (2010) 116 (21): 55.

https://doi.org/10.1182/blood.V116.21.55.55

Published: 2010

Journal Articles

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Heather K Webb, Ph.D., Hao Chen, Ph.D., Albert S Yu, M.D., Sissy Peterman, Leanne Holes, Brian Lannutti, PhD, Langdon L. Miller, MD, Roger G Ulrich, Ph.D.

Blood (2010) 116 (21): 1774.

https://doi.org/10.1182/blood.V116.21.1774.1774

Published: 2010

Journal Articles

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad Kahl, MD, John C. Byrd, MD, Ian W. Flinn, MD, PhD, Nina Wagner-Johnston, MD, Stephen Spurgeon, MD, Don M Benson, Jr, MD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Steven Coutre, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Roger G Ulrich, Ph.D., Heather K Webb, Ph.D., Sissy Peterman, Leanne Holes, Albert S Yu, MD

Blood (2010) 116 (21): 1777.

https://doi.org/10.1182/blood.V116.21.1777.1777

Published: 2010

Journal Articles

Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia

Sarah E.M. Herman, Rosa Lapalombella, Jeffrey A. Jones, MD, MPH, Leslie Andritsos, MD, Amber L. Gordon, Asha Ramanunni, Brian Lannutti, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2010) 116 (21): 1821.

https://doi.org/10.1182/blood.V116.21.1821.1821

Published: 2010

NARROW

Three BTK-Specific Inhibitors, in Contrast to Ibrutinib, Do Not Antagonize Rituximab-Dependent NK-Cell Mediated Cytotoxicity

The PI3K Delta Inhibitor Idelalisib Interferes With Pre-B Cell Receptor Signaling In Acute Lymphoblastic Leukemia (ALL): A New Therapeutic Concept

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

Phosphoinositide 3’-Kinase (PI3K) Delta Inhibition with CAL-101 Blocks B-Cell Receptor (BCR) Signaling and the Prosurvival Actions of Nurslike Cells (NLC), In Chronic Lymphocytic Leukemia

CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Clinical Pharmacokinetics of CAL-101, a p110δ Isoform-Selective PI3K Inhibitor, Following Single- and Multiple-Dose Administration In Healthy Volunteers and Patients with Hematological Malignancies

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase-δ Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only